Avilar Therapeutics
Extracellular protein degrader platform for targeted protein destruction
- Sector
- Biotech
- Founded
- 2020
- Latest Form D
- $20.3M, Dec 2020
- Total capital
- $20.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $20.3M
- 1 Form D · last Dec 2020
- 70 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2023
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$20.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- ADAM MUZIKANTExecutive OfficerNamed in SEC Form D filings
- DANIEL GRAUExecutive Officer, DirectorNamed in SEC Form D filings
- David NeafusExecutive OfficerNamed in SEC Form D filings
- Joshua ResnickDirectorNamed in SEC Form D filings
- MARTIN FREEDDirectorNamed in SEC Form D filings
- Milind DeshpandeExecutive Officer, DirectorNamed in SEC Form D filings
Show all 10 people
- PAULINA HILLDirectorNamed in SEC Form D filings
- PHIL GRAHAMExecutive OfficerNamed in SEC Form D filings
- STEPHANIE TOZZOExecutive OfficerNamed in SEC Form D filings
- THERESA CAMERONDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- PendingAsgpr-binding Compounds For The Delivery Of OligonucleotidesUSPTOApplication 19572253
- GrantedAsgpr-binding Compounds For The Degradation Of Extracellular ProteinsUSPTOUS 12,667,620
- PendingMannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular ProteinsUSPTOApplication 19316915
Show all 40 patent records
- Asgpr-binding Compounds For The Delivery Of OligonucleotidesJul 23, 2026 · Application 19572253Pending
- Asgpr-binding Compounds For The Degradation Of Extracellular ProteinsJun 30, 2026 · US 12,667,620Granted
- Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular ProteinsMay 14, 2026 · Application 19316915Pending
- Asgpr-binding Compounds For The Degradation Of Extracellular ProteinsMay 12, 2026 · US 12,622,972Granted
- Potent Asgpr-binding Heterobifunctional Compounds For The Degradation Of Immunoglobulins And Other ProteinsMar 26, 2026 · Application 19179878Pending
- Potent Asgpr-binding Compounds For The Degradation Of Immunoglobulins And Other ProteinsJul 10, 2025 · Application 19081912Pending
- Potent Asgpr-binding Compounds For The Degradation Of Immunoglobulins And Other ProteinsMay 27, 2025 · US 12,312,340Granted
- Asgpr-binding Compounds For The Degradation Of Extracellular ProteinsMay 6, 2025 · US 12,290,568Granted
- Asgpr-binding Compounds For The Degradation Of Extracellular ProteinsApr 22, 2025 · US 12,280,116Granted
- Asgpr-binding Compounds For The Degradation Of Extracellular ProteinsOct 29, 2024 · US 12,128,106Granted
- Potent Asgpr-binding Compounds For The Degradation Of Immunoglobulins And Other ProteinsSep 17, 2024 · US 12,091,402Granted
- Asgpr-binding Compounds For The Degradation Of Extracellular ProteinsSep 3, 2024 · US 12,076,408Granted
- Mannose 6-PHOSPHATE Or Asgpr Receptor Binding Compounds For The Degradation Of Extracellular ProteinsJul 18, 2024 · Application 18586086Pending
- Asgpr-binding Compounds For The Degradation Of Extracellular ProteinsNov 21, 2023 · US 11,819,551Granted
- Asgpr-binding Compounds For The Delivery Of OligonucleotidesApplication PCTUS2024047557Pending
- ApoB DEGRADING COMPOUNDS AND USES THEREOFApplication PCTUS2024054275Pending
- Asgpr-binding Compounds For The Delivery Of OligonucleotidesApplication 63637788Pending
- Mannose 6-PHOSPHATE Receptor Binding Compounds For The Degradation Of Extracellular ProteinsApplication PCTUS2024018217Pending
- Potent Asgpr-binding Heterobifunctional Compounds For The Degradation Of Targeted Extracellular ProteinsApplication 63760990Pending
- Potent Asgpr-binding Heterobifunctional Compounds Comprising Antibodies For The Degradation Of Targeted ProteinsApplication 63774677Pending
- ASGPR-Binding Compounds for the Degradation of LipoproteinsApplication 63547325Pending
- Potent Asgpr-binding Heterobifunctional Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication PCTUS2023078749Pending
- Asgpr-binding Compounds For The Delivery Of OligonucleotidesApplication 63539206Pending
- Potent Asgpr-binding Heterobifuctional Compounds For The Degradation Of Targeted Extracellular ProteinsApplication PCTUS2025028494Pending
- Potent Asgpr-binding Heterobifunctional Compounds Comprising Antibodies For The Degradation Of Targeted ProteinsApplication PCTUS2025028469Pending
- Potent Asgpr-binding Heterobifunctional Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication 63449553Pending
- Mannose 6-PHOSPHATE Receptor Binding Compounds For The Degradation Of Extracellular ProteinsApplication 63449542Pending
- Potent Asgpr-binding Heterobifunctional Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication 63424442Pending
- Potent Asgpr-binding Heterobifunctional Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication 63422369Pending
- Mannose 6-PHOSPHATE Or Asgpr Receptor Binding Compounds For The Degradation Of Extracellular ProteinsApplication PCTUS2022041738Pending
- Methods To Reduce Adverse Effects Of Gene Or Biologics TherapyApplication PCTUS2022038397Pending
- Potent Asgpr-binding Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication PCTUS2022027513Pending
- Potent Asgpr-binding Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication 63331592Pending
- Mannose 6-PHOSPHATE Or Asgpr Receptor Binding Compounds For The Degradation Of Extracellular ProteinsApplication 63293432Pending
- Potent Asgpr-binding Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication 63293447Pending
- Mannose 6-PHOSPHATE Or Asgpr Receptor Binding Compounds For The Degradation Of Extracellular ProteinsApplication 63245460Pending
- Mannose 6-PHOSPHATE Or Asgpr Receptor Binding Compounds For The Degradation Of Extracellular ProteinsApplication 63238013Pending
- In Vivo Assembly Of Asgpr Binding TherapeuticsApplication PCTUS2021045602Pending
- Potent Asgpr-binding Compounds For The Degradation Of Immunoglobulins And Other ProteinsApplication 63228067Pending
- Bifunctional Molecules And Uses ThereofApplication 63225746Pending
Related companies, and why
- MethylGene Inc.Similar federal contract value in Biotech · null in contracts
- OtonomySimilar federal contract value in Biotech · null in contracts
- Endlyz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SUPERNUS PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Siolta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- PEPTIDE LOGIC LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .